Bart Bergstein
Président chez ISA Pharmaceuticals BV
Profil
Bart Bergstein is the founder of Forbion Co-Investment II Coöperatief UA (founded in 2000) and Forbion Capital Partners Management Holding BV (founded in 2007).
He is currently Vice Chairman at Stichting Publieke Private Samenwerking Versterking, Chairman-Supervisory Board at ISA Pharmaceuticals BV, and Director at CEVEC Pharmaceuticals GmbH.
He previously held positions as Director-Supervisory Board at Ardana Plc, Licentec, and AM-Pharma BV, Director at Cytheris SA and Mimetas BV, and Chief Financial Officer at Cellnovo Group SA. Bergstein received an undergraduate degree from Technische Universiteit Eindhoven.
Postes actifs de Bart Bergstein
| Sociétés | Poste | Début |
|---|---|---|
Stichting Publieke Private Samenwerking Versterking
 Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Directeur/Membre du Conseil | 22/06/2011 |
CEVEC Pharmaceuticals GmbH
 CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany. | Directeur/Membre du Conseil | - |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Président | - |
Anciens postes connus de Bart Bergstein
| Sociétés | Poste | Fin |
|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Fondateur | 01/03/2014 |
Forbion Co-Investment II Coöperatief UA
 Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch. | Fondateur | - |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Directeur/Membre du Conseil | - |
| CELLNOVO | Directeur Financier/CFO | - |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Directeur/Membre du Conseil | - |
Formation de Bart Bergstein
| Technische Universiteit Eindhoven | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Ardana Plc
 Ardana Plc Pharmaceuticals: MajorHealth Technology Ardana Plc developed pharmaceuticals products. It offered Invicorp, an intracavernosal injectable combination of phentolamine mesilate and vasoactive intestinal polypeptide for the treatment of male erectile dysfunction. The company was founded in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany. | Health Technology |
Forbion Co-Investment II Coöperatief UA
Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch. | Finance |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
Licentec
 Licentec Miscellaneous Commercial ServicesCommercial Services Licentec provides evaluation of technology, patents, licensing, and IP management services. It offers support services to universities, knowledge institutions, companies, venture capitalists, and entrepreneurs in the commercialization of technology. The company was founded in 1978 and is headquartered in Bilthoven, the Netherlands | Commercial Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Stichting Publieke Private Samenwerking Versterking
Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Miscellaneous |
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Health Technology |
Cellnovo Group SA
 Cellnovo Group SA Medical SpecialtiesHealth Technology Cellnovo Group SA was a medical technology company, which specialized in diabetes. The company developed and marketed the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. It products portfolio included system, switch, pump therapy, and patient stories. The company was founded by Julian Shapley on December 15, 2014 and was headquartered in Paris, France. | Health Technology |
